Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.90 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.71 |
| ▸ | CA9 | Q16790 | 3/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | PTGES | O14684 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | PDE5A | O76074 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CA3 | P07451 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8121503 | 0.94 | PTGS2 (0.83) | CYP2C9PTGS2PTGS1CA9PDPK1 | |
| SCHEMBL18180817 | 0.94 | CYP2C9 (0.80) | CYP2C9PTGS2PTGS1CA9PDPK1 | |
| SCHEMBL212983 | 0.94 | PTGS2 (0.83) | CYP2C9PTGS2PTGS1CA9PDPK1 | |
| SCHEMBL2602400 | 0.88 | PTGS2 (0.80) | CYP2C9PTGS2PTGS1CA9PDPK1 | |
| SCHEMBL8420247 | 0.88 | CYP2C9 (0.71) | CYP2C9PTGS2PTGS1CA9PDPK1 | |
| SCHEMBL8125344 | 0.88 | CYP2C9 (0.71) | CYP2C9PTGS2PTGS1 | |
| SCHEMBL20042404 | 0.87 | CYP2C9 (0.78) | CYP2C9PTGS2PTGS1CA9PDPK1 | |
| SCHEMBL6452272 | 0.87 | PTGS2 (0.92) | CYP2C9PTGS2PTGS1CA9CA1 | |
| SCHEMBL18180816 | 0.87 | CYP2C9 (0.77) | CYP2C9PTGS2PTGS1CA9PDPK1 | |
| SCHEMBL5698697 | 0.86 | PTGS2 (0.88) | CYP2C9PTGS2PTGS1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-0932402-B1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | SEARLE LLC (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| EP-1416940-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | Pharmacia Corporation (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1416941-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | Pharmacia Corporation (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2003015799-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| CN-1398189-A | Combination therapy of radiation and COX-2 inhibitor for treatment of neoplasia | SEARLE & CO (US) | 2003-02-19 | — | — | CN | claimed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| US-6469040-B2 | ADMINISTERING 1-(P-AMINOSULFONYL)PHENYL-3-HALOALKYL-5-PHENYLPYRAZOLES | G.D. SEARLE & CO. | 2002-10-22 | — | — | US | claimed |
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | claimed |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | RONIKER BARBARA (US) | 2002-03-21 | — | — | US | claimed |
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. SEARLE & CO. | 2001-11-29 | — | — | US | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PTGIR, VASP, TRPV2 | CYP2C9 447/4885PTGS2 4/4885PTGS1 8/4885 |
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | PTGS2, PTGES2, PTGS1 | CYP2C9 755/4885PTGS2 1/4885PTGS1 3/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | CYP2C9 981/4885PTGS2 2/4885PTGS1 1/4885 |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | FABP3, TNNT2, TNNI3 | CYP2C9 1444/4885PTGS2 6/4885PTGS1 20/4885 |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | APP, BACE2, PTGS2 | CYP2C9 2425/4885PTGS2 3/4885PTGS1 9/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | CYP2C9 733/4885PTGS2 1/4885PTGS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.